Position in NVAX
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$3,749
+$510 QoQ
Shares Held
398
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#214
of 263 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 64%
Shared 0%
None 36%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026FINANCIAL CONSULATE, INC holds $504,194 across 31 Biotechnology names. NVAX ranks #16 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
800 | $195,816 | |
| 2 | ARGX |
Argenx SE
|
107 | $99,271 | |
| 3 | RPRX |
Royalty Pharma plc
|
1,000 | $56,070 | |
| 4 | BNTX |
BioNTech SE
|
370 | $34,428 | |
| 5 | MRNA |
Moderna, Inc.
|
340 | $23,810 | |
| 6 | PCVX |
Vaxcyte, Inc.
|
250 | $14,532 | |
| 7 | CVM |
Cel Sci Corp
|
10,000 | $10,400 | |
| 8 | SLS |
SELLAS Life Sciences Group, Inc.
|
600 | $8,856 |
All Filings in NVAX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,749 | 398 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $3,239 | 398 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $2,674 | 398 | Shares | Sole | 2026-01-22 | |
| 2025-09-30 | $3,450 | 398 | Shares | Sole | 2025-10-21 | |
| No filing history on record for this holder in this stock. | ||||||